A Phase 3 interventional study of memantine ER and Placebo in Dementia of the Alzheimer's Type, sponsored by Forest Laboratories. Completed at 83 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2010-09-16.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.
Among the 34 studies testing memantine in Alzheimer Disease, this one has the largest enrollment, is one of 4 that started in 2005, is one of 8 in phase 3, and was the 6th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–32
By country, each count listing its studies:
Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 21
First in 2003; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 677 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 90 across the 34 interventional studies. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
27 studies in Alzheimer Disease by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 6 (25%) have results posted.
Among the 27 studies in Alzheimer Disease by AbbVie, this one has the largest enrollment, is one of 2 that started in 2005, is one of 3 in phase 3, and was the 3rd registered.
AbbVie’s Alzheimer Disease studies by the year they started, since 2003.
1 of the studies testing memantine in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05063851University of VirginiaThe Use of Memantine for Prevention of Alzheimer's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing memantine in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 27 in Alzheimer Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
Memantine is a therapeutic agent that represents a unique class of Alzheimer's disease (AD) treatment options. A once daily (QD) dosing regimen in an AD population would simplify administration for the caregiver. The purpose of this study is to evaluate the safety and efficacy of modified release memantine taken once daily in outpatients with moderate-to-severe AD on a concurrent AChEI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration, once daily.
Drug: Placebo
28mg, once daily. Oral administration for 24 weeks.
Drug: memantine ER
28mg(7mg capsules) once daily and oral administration for 24 weeks.
Also known as: Namenda XR
Matching placebo oral administration once daily.
Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)
The SIB was developed for the evaluation of cognitive function in patients with more advanced dementia, and evaluates the areas of memory, language, praxis, orientation, and attention. The SIB test items consist of simple, one-step commands presented with gestural cues that are repeated if necessary. The test contains 51 items, and the range of possible scores is 0 to 100 (with 0 being the worst result). The SIB has been shown to be a valid and reliable instrument sensitive to longitudinal change.
Time frame: Baseline to week 24
Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)
The CIBIC-Plus is a measure of an overall clinical effect and is based on a comprehensive evaluation at Baseline and later visits of four domains: general (overall clinical status), functional (including activities of daily living), cognitive, and behavioral. A skilled clinician interviews the patient, and includes information supplied by a knowledgeable caregiver. The CIBIC-Plus is a rating of the patient's global status relative to Baseline, ranging from a score of 1, indicating "marked improvement" to a score of 4, indicating "no change" to a score of 7, indicating "marked worsening."
Time frame: Week 24
Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)
The ADCS-ADL19 modified inventory consists of 19 items used to measure the functional capabilities of patients with moderate to severe dementia. Each activity-of-daily-living (ADL) item comprises a series of hierarchical subquestions ranging from the highest level of independent performance to complete loss of ability to perform the ADL Inventory. The inventory is performed by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Response range is 0 (total disability) to 54 (total independence).
Time frame: Baseline to week 24
The recruitment period was from May 20, 2005 to April 18th, 2007 at 83 study centers in four countries (23 in Argentina, 11 in Chile, 11 in Mexico, and 38 in the US)
| Milestone | Placebo | Memantine ER |
|---|---|---|
| Started | 335 | 342 |
| Safety population | 335 | 341 |
| Completed | 272 | 273 |
| Not completed | 63 | 69 |
| Withdrew: Adverse event | 21 | 34 |
| Withdrew: Protocol violation | 6 | 14 |
| Withdrew: Withdrawal by subject | 18 | 10 |
| Withdrew: Lack of efficacy | 8 | 3 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Withdrawn for other reasons | 5 | 4 |
The SIB was developed for the evaluation of cognitive function in patients with more advanced dementia, and evaluates the areas of memory, language, praxis, orientation, and attention. The SIB test items consist of simple, one-step commands presented with gestural cues that are repeated if necessary. The test contains 51 items, and the range of possible scores is 0 to 100 (with 0 being the worst result). The SIB has been shown to be a valid and reliable instrument sensitive to longitudinal change.
| Units on a scale | Placebo | Memantine ER |
|---|---|---|
| Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF) | -0.4 ± 0.65 | 2.2 ± 0.65 |
The CIBIC-Plus is a measure of an overall clinical effect and is based on a comprehensive evaluation at Baseline and later visits of four domains: general (overall clinical status), functional (including activities of daily living), cognitive, and behavioral. A skilled clinician interviews the patient, and includes information supplied by a knowledgeable caregiver. The CIBIC-Plus is a rating of the patient's global status relative to Baseline, ranging from a score of 1, indicating "marked improvement" to a score of 4, indicating "no change" to a score of 7, indicating "marked worsening."
| Units on a scale | Placebo | Memantine ER |
|---|---|---|
| Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF) | 4.1 ± 0.07 | 3.8 ± 0.07 |
The ADCS-ADL19 modified inventory consists of 19 items used to measure the functional capabilities of patients with moderate to severe dementia. Each activity-of-daily-living (ADL) item comprises a series of hierarchical subquestions ranging from the highest level of independent performance to complete loss of ability to perform the ADL Inventory. The inventory is performed by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Response range is 0 (total disability) to 54 (total independence).
| Units on a scale | Placebo | Memantine ER |
|---|---|---|
| Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF) | -1.7 ± 0.44 | -1.0 ± 0.44 |
Collected over Occurring on or after the date of the first dose of double-blind study medication and within 30 days of the date of last dose of double-blind study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 21/335 (6.3%) | 70/335 (20.9%) |
| Memantine ER | — | 28/341 (8.2%) | 67/341 (19.6%) |
| Event | Placebo | Memantine ER |
|---|---|---|
| FallInjury, poisoning and procedural complications | 5/335 | 2/341 |
| Cardiac Failure CongestiveCardiac disorders | 3/335 | 0/341 |
| Urinary tract infectionInfections and infestations | 3/335 | 2/341 |
| Hip fractureInjury, poisoning and procedural complications | 3/335 | 0/341 |
| Cardio-respiratory arrestCardiac disorders | 2/335 | 0/341 |
| PneumoniaInfections and infestations | 0/335 | 2/341 |
| Cerebrovascular accidentNervous system disorders | 0/335 | 2/341 |
| SyncopeNervous system disorders | 0/335 | 2/341 |
| BradycardiaCardiac disorders | 1/335 | 1/341 |
| Cardiac ArrestCardiac disorders | 1/335 | 0/341 |
| Event | Placebo | Memantine ER |
|---|---|---|
| FallInjury, poisoning and procedural complications | 26/335 | 19/341 |
| Urinary tract infectionInfections and infestations | 24/335 | 19/341 |
| HeadacheNervous system disorders | 17/335 | 19/341 |
| DiarrhoeaGastrointestinal disorders | 13/335 | 17/341 |
| Age, Customized(participants) | Placebo | Memantine ER | Total |
|---|---|---|---|
| <= 64 years | 26 | 34 | 60 |
| 65-74 years | 79 | 85 | 164 |
| 75-84 years | 179 | 176 | 355 |
| >= 85 years | 51 | 46 | 97 |
| Age Continuous(years) | Placebo | Memantine ER | Total |
|---|---|---|---|
| Mean | 76.8 ± 7.76 | 76.2 ± 8.35 | 76.5 ± 8.07 |
| Sex: Female, Male(Participants) | Placebo | Memantine ER | Total |
|---|---|---|---|
| Female | 243 | 244 | 487 |
| Male | 92 | 97 | 189 |
| Region of Enrollment(participants) | Placebo | Memantine ER | Total |
|---|---|---|---|
| United States | 85 | 93 | 178 |
| Argentina | 158 | 153 | 311 |
| Chile | 44 | 46 | 90 |
| Mexico | 48 | 49 | 97 |
The record gives a start of Jun 2005, a primary completion of Oct 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine